ChemicalBook > Product Catalog >API >Blood System Drugs >Anticoagulant and Antiplatelet Drugs >Dabigatran etexilate

Dabigatran etexilate

Dabigatran etexilate Suppliers list
Company Name: Jinan Jianfeng Chemical Co., Ltd
Tel: 15562555968
Products Intro: Product Name:Dabigatran etexilate
Purity:99% Package:5KG;1KG
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Products Intro: Product Name:Dabigatran etexilate
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Products Intro: Product Name:Dabigatran etexilate
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Products Intro: CAS:211915-06-9
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Shanghai Yingrui Biopharma Co., Ltd.
Tel: +86-21-33585366
Products Intro: Product Name:Dabigatranetexilate
Purity:99% Package:100g;500g;1kg;25kg...

Lastest Price from Dabigatran etexilate manufacturers

  • Dabigatran etexilate
  • US $2.00 / KG
  • 2018-08-08
  • CAS:211915-06-9
  • Min. Order: 1KG
  • Purity: 99%
  • Supply Ability: 20kg
Dabigatran etexilate Basic information
Indications and Usage Mechanisms of Action Clinical Research Warnings and Precautions
Product Name:Dabigatran etexilate
Synonyms:Dabigatran Etexilatr;BIBR-1048(Dabigatran etexilate);N-[2-[4-[N-(Hexyloxycarbonyl)aMidino]phenylaMinoMethyl]-1-Methyl-1H-benziMidazol-5-ylcarbonyl]-N-(2-;BIBR 1048;BIBR-1048;Prazaxa;(E)-ethyl 3-(2-((4-(N'-(hexyloxycarbonyl)carbamimidoyl)phenylamino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate;BIBR-1048, >=99%
Product Categories:-;Pharmaceutical intermediate;API;Dabigatran etexilate;Other APIs
Mol File:211915-06-9.mol
Dabigatran etexilate Structure
Dabigatran etexilate Chemical Properties
Melting point 128-129°
Safety Information
MSDS Information
Dabigatran etexilate Usage And Synthesis
Indications and UsageDabigatran is the newest generation of oral anticoagulant drugs – direct thrombin inhibitors (DTIs), belonging to non-peptide thrombin inhibitors and instead specifically and selectively blocks the thrombin activity (free or bound) to prevent coagulation. Dabigatran targets the preventative and clinical treatment needs of acute and chronic thromboembolic disease.
Mechanisms of ActionIt achieves anticoagulant effects through specific and selective inhibition of blood enzymes (free or bound). After oral ingestion and absorption through the digestive system, Dabigatran turns into Dabiga groups that have the direct anticoagulant abilities. By binding to thrombin in fibrin specific binding sites, Dabigatran stops fibrinogen from cleaving into fibrin, thus interrupting the blood clotting network and consequently thrombosis. Dabiga groups can also dissociate from the fibrin-thrombin coagulate and have an anticoagulating effect. Different from vitamin K antagonists, which affect different coagulants, Dabigatran can provide effective, predictable and stable anticoagulant effects. It will also have minimal reactions to other drugs or food, and does not require frequent monitoring or dosage adjustment.
Clinical ResearchCompared to the control group treated with Warfarin, Dabigatran can significantly decrease the risk of stroke and embolic disease (including hemorrhagic stroke), greatly reduce the occurrence of bleeding (including fatal bleeding and intracranial hemorrhage), and greatly lower vascular mortality rate. Dabigatran provides effective and stable anticoagulant effects and does not require constant monitoring of anticoagulant functions or dosage adjustments.
Warnings and Precautions1. Dabigatran is not to be used by patients with severe kidney damage (CrCl<30ml/min).
2. Patients with high bleeding risk should also not use Dabigatran.
3. Patients must be tested and monitored for signs of lack of bleeding or anemia; if there is severe bleeding, cease use of Dabigatran and identify the bleeding area.
4. Dabigatran is not suitable for patients with significant manifestations of rheumatic valvar heart disease or patients with artificial heart valves.
UsesBIBR-1048 (Dabigatran) is an anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in many cases it offers an alternative to warfarin as the preferred orally administered blood thinner sin
DefinitionChEBI: An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amino group of thyl N-pyridin-2-yl-beta-alaninate. A prodrug for dabigatran, a thrombin inhibitor and anticoagulant which is used for the prevention of stroke and systemic embolism.
Dabigatran etexilate Preparation Products And Raw materials
Tag:Dabigatran etexilate(211915-06-9) Related Product Information
Dabigatran Etexilate iMpurity D Dabigatran iMpurity E Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate (Dabigatran IMpurity) Dabigatran iMpurity F Pravastatin sodium Bortezomib Imatinib mesylate Panobinostat Torin 1 Carfilzomib Rivaroxaban Dabigatran Dabigatran Etexilate Mesylate